🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-525158-20-00
Ongoing Phase I

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

2025-525158-20-00 · tracked via the Priya Life Science EU tracker
Sponsor
Biocon Biologics UK PLC
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
22/06/2026
Enrollment target
43
Sites
Spain, Romania

Condition studied

Stage IIB/C, Stage III, or Stage IV Melanoma

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-525158-20-00 on CTIS ↗ ← All trials in the EU